Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures from Eli Lilly for two ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Uh, David Ricks, would be one of them, the CEO of Lilly. I think that you don't have comorbidities with these and it's going ...
We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...